A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
Public ClinicalTrials.gov record NCT00046072. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis
Study identification
- NCT ID
- NCT00046072
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Interventions
- E5564 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2001
- Primary completion
- Not listed
- Completion
- Mar 31, 2005
- Last update posted
- Dec 11, 2005
2001 – 2005
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Mobile | Alabama | 36608 | — |
| Not listed | San Diego | California | 92134 | — |
| Not listed | Santa Barbara | California | 93105 | — |
| Not listed | Jacksonville | Florida | 32209 | — |
| Not listed | Miami | Florida | 33125 | — |
| Not listed | Pensacola | Florida | 32504 | — |
| Not listed | Columbus | Georgia | 31902 | — |
| Not listed | Elk Grove | Illinois | 60007 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Springfield | Massachusetts | 01199 | — |
| Not listed | Buffalo | New York | 14203 | — |
| Not listed | Manhasset | New York | 11030 | — |
| Not listed | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Dallas | Texas | 75390 | — |
| Not listed | Galveston | Texas | 77555 | — |
| Not listed | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00046072, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 11, 2005 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00046072 live on ClinicalTrials.gov.